Quotient Sciences SME comments on solubility & bioavailability challenges in Drug Development & Delivery feature article
John McDermott, Quotient Sciences' Executive Drug Development Consultant, discusses Integrated Development Strategies Overcome Solubility Challenges, in Drug Development & Delivery's Special Feature.
Quotient Sciences featured in Drug Development & Delivery's Outsourcing Formulation Development & Manufacturing Special Feature
Dr. Sarah Stevens, Quotient Sciences' VP of Drug Development Sciences, discusses our recent acquisition of Arcinova and the integration of drug substance, drug product, and clinical testing capabilities – all under one organization, in Drug Development & Delivery's Special Feature Report
South Rampart Pharma Announces Patient Enrollment and Dosing Underway in Phase 1 Study Evaluating Novel Non-Opioid Approach to Pain with Lead Program, SRP-3D (DA)
SRP-3D (DA) has demonstrated a compelling safety profile over currently available pain medications Potential to address the significant unmet need for new, safe, effective, and non-opioid pain medications Development program funded by the National Institutes of Health (NIH) through a Small Business Technology Transfer (STTR) Fast Track Grant Topline results expected Q3 2022
Clinical Trials Arena Interview with Stuart McDougall, VP of Bioanalytical Services on bioanalytical and pharmacokinetics (PK) strategies
Quotient's VP of Bioanalytical Services, Stuart McDougall was featured in an interview with Clinical Trials Area discussing the Bioanalytical and Pharmacokinetics (PK) strategies at Quotient, and how we reduce risk and delay within the drug development process.
Oxilio OXL001 formulation optimisation and clinical trial preparation contract with Quotient Sciences
Oxilio OXL001 formulation optimisation and clinical trial preparation contract with Quotient Sciences Oxilio Ltd is a privately held pharmaceutical development company focused on repurposing known drugs for the treatment of cancer through a programme of corporate alliances coupled with rapid proof of concept clinical development.
Quotient Sciences Completes Integration of Drug Substance Into Translational Pharmaceutics Platform
Quotient Sciences completes integration of drug substance into Translational Pharmaceutics® Platform. The newly enhanced drug development platform will help empower innovators with the fastest development timelines